Adalimumab-Induced Cutaneous Lupus Erythematosus: Cases Presenting With Malar Rash and Panniculitis

Area of Science:

• Dermatology
• Immunology
• Rheumatology

Background:

• Tumor necrosis factor-alpha (TNF-α) inhibitors are widely used for autoimmune diseases.
• Rarely, these therapies can induce cutaneous lupus erythematosus (LE).
• Adalimumab is a common TNF-α inhibitor used for psoriasis.

Purpose of the Study:

• To report cases of drug-induced cutaneous lupus.
• To highlight paradoxical reactions to TNF-α inhibitors.
• To emphasize timely diagnosis and management of cutaneous LE secondary to adalimumab.

Main Methods:

• Case report presentation.
• Review of patient history and clinical presentation.
• Analysis of treatment and outcomes.

Main Results:

• Two women (38 and 61 years old) developed cutaneous LE after adalimumab therapy for psoriasis.
• The cutaneous lupus was an isolated reaction.
• Adalimumab treatment was associated with the onset of LE.

Conclusions:

• Adalimumab can induce cutaneous lupus erythematosus.
• Physicians must be aware of this rare paradoxical reaction.
• Early recognition and management are essential for patient outcomes.